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Abstract
Background The consequences of lymphadenectomy (LND) on cirrhotic patients undergoing hepatectomy for
intrahepatic cholangiocarcinoma (ICC) have not been investigated. We sought to analyze the impact of LND on
morbidity among patients undergoing resection for ICC.
Methods A total of 1005 patients who underwent hepatectomy for ICC at one of the 14 participating institutions
between 1990 and 2015 were identified. A propensity score match analysis was performed to reduce confounding
biases between cirrhosis and non-cirrhosis groups.
Results Cirrhosis was diagnosed in 118 (11.7%) patients. Among non-cirrhotic patients, 63% underwent major liver
resection versus only 20% among patients with cirrhosis (p\ 0.001). LND was also less common among cirrhotic
versus non-cirrhotic patients (19 vs. 50%, p\ 0.001). The incidence of complications was 41 and 30% among
patients who did not and did have cirrhosis, respectively (p = 0.022). The propensity-matched cohort included 150
patients. The incidence of complications was 71% among patients who underwent lymphadenectomy versus 23%
among patients who did not undergo lymphadenectomy (OR 8.39) (p\ 0.001). In the propensity-matched analysis,
the median HLN was comparable among patients independent of cirrhosis status (median HLN: non-cirrhosis, 2.5 vs.
cirrhosis, 2) (p = 0.95). While lymphadenectomy was associated with a higher risk of infections (non-cirrhosis, 0%
vs. cirrhosis, 21%, p\ 0.001) among patients with cirrhosis, infections were not associated with lymphadenectomy
among non-cirrhotic patients (p = 0.19).
Conclusion Lymphadenectomy was associated with an increased risk of complications among patients with cirrhosis
undergoing surgery for ICC. The benefit of lymphadenectomy in cirrhotic patients should be considered in light of
the higher risk of postoperative complications compared with non-cirrhotic patients.
Introduction
A variety of liver diseases including intrahepatic lithiasis,
primary sclerosing cholangitis, congenital abnormalities of
the bile ducts, and liver fluke infection can induce a state of
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chronic biliary inflammation resulting in severe fibrosis
and cirrhosis of the underlying liver parenchyma [1–3].
Several studies have identified cirrhosis as a risk factor for
the development of intrahepatic cholangiocarcinoma (ICC)
[1, 2, 4–6]. In fact, a strong association between HCV-
related cirrhosis and ICC [7, 8] and a weaker but consistent
association between HBV-related cirrhosis and ICC have
been identified [9]. Furthermore, cirrhosis associated with
metabolic syndrome, steatohepatitis, and non-alcoholic
fatty liver disease (NAFLD) has been linked to an
increased risk of ICC [10, 11]. A population-based analysis
using the Surveillance, Epidemiology, and End Results
(SEER) database confirmed a strong association between
cirrhosis and ICC [12].
Recently, the 8th edition of the American Joint Com-
mittee on Cancer (AJCC) staging manual emphasized the
importance of adequate nodal staging for ICC [13]. The
manual called for a minimum of six harvested lymph nodes
(HLN) for adequate nodal staging. The potential implica-
tions of performing lymphadenectomy among patients with
ICC and cirrhosis have not been investigated. This topic is
of particular importance because the subset of patients with
cirrhosis may be at increased risk of morbidity [14]. For
example, Lee et al. [15] reported that patients with cirrhosis
who underwent gastrectomy and a D2 lymphadenectomy
for gastric cancer had a higher incidence of postoperative
complications of up to 40%. In a separate study, Tachibana
et al. [16] reported that the incidence of postoperative
complication was as high as 80% among patients with
cirrhosis who underwent esophagectomy combined with an
extended lymphadenectomy.
While the impact of cirrhosis on morbidity related to
hepatectomy has been well defined [17], the possible
increase in morbidity related to lymphadenectomy among
patients with ICC and cirrhosis has not been examined.
Therefore, the objective of the current study was to define
the impact of cirrhosis on lymphadenectomy utilization
relative to short-term outcomes following surgery for ICC
using a large multi-institutional international dataset.
Patients and methods
Study population and data collection
Patients who underwent hepatectomy for ICC at one of 14
hepatobiliary centers between 1990 and 2015 were identi-
fied (Supplementary Methods). Only patients who under-
went curative-intent hepatectomy for ICC without
extrahepatic metastasis were included. Patients who
underwent only non-surgical treatments such as percuta-
neous ablation or intra-arterial therapy were excluded.
Standard patient demographic and clinicopathological
characteristics were collected including age, gender,
American Society of Anesthesiologist (ASA) class, serum
level of CA19-9, morphological type, number of ICC,
tumor size, invasion of adjacent organs, liver capsule
involvement, margin status, tumor grade, major vascular
invasion, lymphovascular invasion, perineural invasion,
and lymph-nodal status were collected. The diagnosis of
cirrhosis was histologically confirmed. Treatment-related
data such as type and extent of hepatectomy, lym-
phadenectomy, receipt of neoadjuvant, and adjuvant
chemotherapy were also recorded. Tumor stage was cate-
gorized according to the 8th edition of the American Joint
Committee on Cancer (AJCC) [13].
Statistical analysis
Continue variables were described as medians with
interquartile range (IQR), and categorical variables were
recorded as totals and frequencies. Univariable compar-
isons were assessed using Chi-squared test or Fisher’s
exact test as appropriate. To account for any potential
residual confounders regarding the effect of cirrhosis on
postoperative complications, propensity scores matching
was performed (Supplementary Methods). The degrees of
covariate imbalance in unmatched and matched samples
were measured using the standardized differences as pro-
posed by Austin et al. [18]. A p value of\0.10 (two-tailed)
was considered statistically significant. All analyses were
performed using Stata version 12.0 (StataCorp LP, College
Station, TX, USA) or R software for statistical computing,
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v. 3.0.2 34, with the additional packages: Hmisc and
Matching.
Results
Baseline characteristics of patients in non-cirrhosis
and cirrhosis groups
A total of 1005 patients underwent hepatectomy for ICC.
Cirrhosis was present in 118 (11.7%) patients, while 887
(88.3%) patients did not have cirrhosis (Table 1). All
patients who had cirrhosis were Child–Pugh Class A and
well compensated. Several clinical characteristics were
different between the cirrhotic versus non-cirrhotic groups
(Supplementary Materials). At the time of surgery, patients
who did not have cirrhosis (n = 494, 63.2%) more often
underwent a major hepatectomy compared with cirrhotic
patients (20.4%, n = 22) (p\ 0.001). In addition, com-
pared with patients who had cirrhosis, patients who did not
have cirrhosis were more likely to have undergone a con-
comitant bile-duct resection (non-cirrhosis, n = 155,
19.8% vs. cirrhosis, n = 3, 2.8%; p\ 0.001). Of note,
while roughly half of patients without cirrhosis underwent
a lymphadenectomy (n = 445, 50.2%), less than 1 in 5
patients who had cirrhosis had any lymph nodes harvested
at the time of surgery (n = 23, 19.5%) (p\ 0.001). On
pathological assessment, the median HLN was 3 (IQR,
1–6) among patients with cirrhosis compared with 4 (IQR,
2–8) among patients who did not have cirrhosis (p = 0.12).
The median number of metastatic lymph nodes (MLN) was
no different among patients who did (n = 1, IQR, 1–3) and
did not (n = 1, IQR, 1–5) have cirrhosis (p = 0.51). On
pathological assessment, there was also no difference in the
proportion of patients who had R1 surgical margin (R1
margin: non-cirrhosis, n = 123, 14.1% vs. cirrhosis,
n = 10, 8.5%) (p = 0.11).
Following surgery, a total of 395 patients experienced a
complication for an overall morbidity rate of 39.3%. The
incidence of any complication was slightly higher among
patients who did not have cirrhosis (n = 360, 40.6%)
compared with patients who had cirrhosis (n = 35, 29.7%)
(p = 0.022). Particularly, the incidences of renal failure,
pleural effusion, posthepatectomy liver failure (PHLF),
hemorrhages, wound infections, respiratory, and cardio-
vascular complications were not different comparing non-
cirrhosis and cirrhosis groups (all p[ 0.1). In contrast,
patients with cirrhosis group had a lower incidence of bile
leakage and infections after surgery compared with non-
cirrhotic patients (bile leakage: non-cirrhosis, n = 59,
6.6% vs. cirrhosis, n = 3, 2.5%, p = 0.08; infections: non-
cirrhosis, n = 86, 9.7% vs. cirrhosis, n = 4, 3.4%,
p = 0.024; Table 2). Interestingly, there was no difference
Table 1 Clinical and pathological features of the entire study cohort
(n = 1005)
Variables Non-cirrhosis
N (%)
Cirrhosis
N (%)
p value
Patients 887 (88.3%) 118 (11.7%) –
Age, median (IQR) 62 years
(53–70)
56 years
(46–65)
\0.001
Gender \0.001
Female 420 (47.4%) 22 (18.6%)
Male 467 (52.6%) 96 (81.4%)
ASA 0.013
B 2 534 (60.2%) 85 (72.0%)
[ 2 353 (39.8%) 33 (28.0%)
Neoadjuvant
chemotherapy
0.14
No 707 (90.6%) 97 (95.1%)
Yes 73 (9.4%) 5 (4.9%)
Morphological type 0.67
MF, IG 677 (83.1%) 94 (84.7%)
PI, MF ? PI 138 (16.9%) 17 (15.3%)
Type of resections \0.001
Wedge resection 116 (14.9%) 35 (32.4%)
Minor resection 171 (21.9%) 51 (47.2%)
Major resection 494 (63.2%) 22 (20.4%)
Margin status 0.11
R0 749 (85.9%) 108 (91.5%)
R1 123 (14.1%) 10 (8.5%)
Lymph-node status \0.001
Negative 273 (30.8%) 11 (9.3%)
Metastatic 172 (19.4%) 12 (10.2%)
Not harvested 442 (49.8%) 95 (80.5%)
Tumor size \0.001
B5 cm 345 (38.9%) 70 (59.3%)
[5 cm 542 (61.1%) 48 (40.7%)
Liver capsule involvement 0.59
No 758 (85.5%) 103 (87.3%)
Yes 129 (14.5%) 15 (12.7%)
Direct invasion adjacent
organs
0.094
No 748 (95.8%) 107 (99.1%)
Yes 33 (4.2%) 1 (0.9%)
Major vascular resection 0.083
No 633 (80.9%) 94 (87.9%)
Yes 149 (19.1%) 13 (12.2%)
Bile-duct resection \0.001
No 628 (80.2%) 105 (97.2%)
Yes 155 (19.8%) 3 (2.8%)
Grade 0.67
Well/moderate 677 (83.1%) 94 (84.7%)
Poorly/undifferentiated 138 (16.9%) 17 (15.3%)
Microvascular invasion 0.041
No 549 (63.6%) 85 (73.3%)
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in the grade of complication (Clavien–Dindo grade[ 3:
non-cirrhosis, n = 156, 43.3% vs. cirrhosis, n = 13,
37.1%) or length of stay (non-cirrhosis, 13 days vs. cir-
rhosis, 14 days) (both p[ 0.1).
Among the subset of patients who underwent a lym-
phadenectomy (n = 468. 46.6%), the incidence of post-
operative complications was comparable among patients
who did (56.5%) and did not (42.9%) have cirrhosis
(p = 0.21). In addition, among only patients who had cir-
rhosis, lymphadenectomy was associated with risk of
complications (OR 4.31, 95% 1.66–11.2) (p = 0.003).
Among patients who did not have cirrhosis, there was an
increased risk of infections among patients who underwent
lymphadenectomy compared with patients who did not
(infections: no lymphadenectomy, n = 26, 5.9% vs. lym-
phadenectomy, n = 60, 13.5%) (p\ 0.001); several
specific complications were associated with lym-
phadenectomy when performed among cirrhotic patients
(Table 3). Particularly, among patients with cirrhosis,
lymphadenectomy was associated with higher risk of
superficial wound infections (non-cirrhosis, n = 1, 1.0%
vs. cirrhosis, n = 2, 8.7%, p = 0.037) and surgical site
infections (non-cirrhosis, n = 0, 0% vs. cirrhosis, n = 4,
17.4%, p\ 0.001).
Propensity score matching analysis
A propensity score matching was performed to minimize
confounding and create more comparable cohorts
(n = 150) among patients who did and did not have cir-
rhosis (Table 4). After propensity matching, demographic
and clinicopathological characteristics among the cirrhotic
and non-cirrhotic patients were comparable (Table 4). On
propensity-matched analysis, the incidence of postopera-
tive complications was 32.0% (n = 24) in both cohorts of
patients (p[ 0.99; Table 4). Interestingly, among the 24
patients who did not have cirrhosis yet had a complication,
1 (4.2% of 24) patient had a severe complication (Clavien–
Dindo grade of complication C3) versus 5 (20.8% of 24)
patients in the cirrhosis group (p = 0.08). Among patients
who did not have cirrhosis, the incidence of complications
Table 1 continued
Variables Non-cirrhosis
N (%)
Cirrhosis
N (%)
p value
Yes 314 (36.4%) 31 (26.7%)
Perineural invasion 0.002
No 570 (74.7%) 98 (88.3%)
Yes 193 (25.3%) 13 (11.7%)
Multi-focal 0.99
No 744 (83.9%) 99 (83.9%)
Yes 143 (16.1%) 19 (16.1%)
Ca 19–9, median (IQR) 52 (17–232) 31 (17–65) 0.18
CEA, median (IQR) 2.4 (1.4–4.4) 2.4 (1.6–3.9) 0.79
Complication 0.022
No 527 (59.4%) 83 (70.3%)
Yes 360 (40.6%) 35 (29.7%)
Clavien–Dindo grade of
complication*
0.48
1–2 204 (56.7%) 22 (62.7%)
C3 156 (43.3%) 13 (37.1%)
Length of stay, median
(IQR)
13 (8–18) 14 (11–20) 0.12
Overall survival, 5 year
(95% CI)
40.9%
(36.4–45.3)
39.0%
(28.7–49.2)
0.19
*N = 395 patients who had postoperative complications
NA not available, CI confidence interval
Table 2 Type of complications in non-cirrhosis and cirrhosis groups
(n = 1005)
Variables Non-
cirrhosis
N (%)
Cirrhosis
N (%)
p value
Patients 887 (88.3%) 118 (11.7%) –
Respiratory complications 0.25
No 848 (95.6%) 110 (93.2%)
Yes 39 (4.4%) 8 (6.8%)
Cardiovascular
complications
0.56
No 865 (97.5%) 114 (96.6%)
Yes 22 (2.5%) 4 (3.4%)
Renal failure 0.77
No 875 (98.7%) 116 (98.3%)
Yes 12 (1.3%) 2 (1.7%)
Pleura effusion 0.79
No 813 (91.7%) 109 (92.4%)
Yes 74 (8.3%) 9 (7.6%)
Posthepatectomy liver
failure
0.75
No 868 (97.9%) 116 (98.3%)
Yes 19 (2.1%) 2 (1.7%)
Hemorrhage 0.19
No 867 (97.8%) 113 (95.8%)
Yes 20 (2.2%) 5 (4.2%)
Bile leakage 0.08
No 828 (93.4%) 115 (97.5%)
Yes 59 (6.6%) 3 (2.5%)
Wound infection 0.97
No 865 (97.5%) 115 (97.5%)
Yes 22 (2.5%) 3 (2.5%)
Infections 0.024
No 801 (90.3%) 114 (96.6%)
Yes 86 (9.7%) 4 (3.4%)
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was 42.9% (N = 6) among patients who underwent lym-
phadenectomy versus 29.5% (N = 18) among patients who
did not undergo lymphadenectomy (p = 0.33; Fig. 1a). In
contrast, the incidence of complication was 71.4%
(N = 10) among patients who underwent lymphadenec-
tomy versus 22.9% (N = 14) among patients who did not
undergo lymphadenectomy (OR 8.39, 95% CI 2.3–30.9)
(p\ 0.001; Fig. 1b). In the propensity-matched analysis,
the median HLN was comparable among patients inde-
pendent of cirrhosis status (p = 0.95; Fig. 2a) and was not
associated with the occurrence of complications (p = 0.68;
Fig. 2b). While lymphadenectomy was associated with a
higher risk of infections (non-cirrhosis, n = 0, 0% vs.
cirrhosis, n = 3, 21.4%, p\ 0.001) among patients with
cirrhosis, infections were not associated with
lymphadenectomy among patients who did not have cir-
rhosis (p = 0.19) (Supplementary Tables 1S and 2S).
Discussion
Cirrhosis can be a common finding among patients with
liver malignancies. While the association of cirrhosis with
HCC is well established [19], more recent data have
established that cirrhosis can also significantly increase the
risk of ICC [8–10]. In turn, cirrhosis can have important
implications in the peri-operative management of patients
undergoing liver surgery increasing the risk of morbidity
and mortality associated with liver resection [17]. Since
lymphadenectomy is not commonly performed for HCC,
the potential incremental risk of lymph-node dissection in
Table 3 Type of complications in non-cirrhosis and cirrhosis groups for patients who underwent and did not undergo lymphadenectomy
(n = 1005)
Non-cirrhosis
N (%)
p value Cirrhosis
N (%)
p value
No Lymphad. Lymphad No Lymphad. Lymphad
Patients 442 (49.8%) 445 (50.2%) – 95 (80.5%) 23 (19.5%) –
Respiratory complications 0.64 \0.00
No 424 (95.9%) 424 (95.3%) 93 (97.9%) 17 (73.9%) 1
Yes 18 (4.1%) 21 (4.7%) 2 (2.1%) 6 (26.1%)
Cardiovascular complications 0.68 0.00
No 432 (97.7%) 433 (97.3%) 94 (99.0%) 20 (86.9%) 4
Yes 10 (2.3%) 12 (2.7%) 1 (1.0%) 3 (13.0%)
Renal failure 0.57 0.48
No 437 (98.9%) 438 (98.4%) 93 (97.9%) 23 (100%)
Yes 5 (1.1%) 7 (1.6%) 2 (2.1%) –
Pleura effusion
No 387 (87.6%) 426 (95.7%) 89 (93.7%) 20 (86.9%)
Yes 55 (12.4%) 19 (4.3%) \0.001 6 (6.3%) 3 (13.0%) 0.28
Posthepatectomy liver failure 0.81 0.00
No 432 (97.7%) 436 (98.0%) 95 (100%) 21 (91.3%) 4
Yes 10 (2.3%) 9 (2.0%) – 2 (8.7%)
Hemorrhage 0.66 0.24
No 433 (98.0%) 434 (97.5%) 92 (96.8%) 21 (91.3%)
Yes 9 (2.0%) 11 (2.5%) 3 (3.2%) 2 (8.7%)
Bile leakage 0.24 0.037
No 417 (94.3%) 411 (92.4%) 94 (99.0%) 21 (91.3%)
Yes 25 (5.7%) 34 (7.6%) 1 (1.0%) 2 (8.7%)
Wound infection 0.99 0.037
No 431 (97.5%) 434 (97.5%) 94 (99.0%) 21 (91.3%)
Yes 11 (2.5%) 11 (2.5%) 1 (1.0%) 2 (8.7%)
Infections \0.00 \0.00
No 416 (94.1%) 385 (86.5%) 1 95 (100%) 19 (82.6%) 1
Yes 26 (5.9%) 60 (13.5%) – 4 (17.4%)
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Table 4 Clinical and pathological features of patients after propensity score matching analysis (n = 150)
Variables Non-cirrhosis
N (%)
Cirrhosis
N (%)
p value
Patients 75 (50.0%) 75 (50.0%) –
Age, median (IQR) 57 years (48–64) 54 years (46–66) 0.72
Gender 0.57
Female 20 (26.7%) 17 (22.7%)
Male 55 (73.3%) 58 (77.3%)
ASA 0.55
B2 61 (81.3%) 58 (77.3%)
[2 14 (18.7%) 17 (22.7%)
Neoadjuvant chemotherapy 0.30
No 69 (98.6%) 66 (95.6%)
Yes 1 (1.4%) 3 (4.4%)
Morphological type 0.98
MF, IG 70 (95.9%) 71 (95.9%)
PI, MF ? PI 3 (4.1%) 3 (4.1%)
Type of resections 0.97
Wedge resection 23 (32.4%) 23 (32.4%)
Minor resection 32 (45.1%) 33 (46.5%)
Major resection 16 (22.5%) 15 (21.1%)
Margin status 0.47
R0 70 (93.3%) 72 (96.0%)
R1 5 (6.7%) 3 (4.0%)
Lymph-node status 0.93
Negative 9 (12.0%) 8 (10.7%)
Metastatic 5 (6.7%) 6 (8.0%)
Not harvested 61 (81.3%) 61 (81.3%)
Tumor size 0.86
B5 cm 51 (68.0%) 50 (66.7%)
[5 cm 24 (32.0%) 25 (33.3%)
Liver capsule involvement 0.55
No 68 (90.7%) 70 (93.3%)
Yes 7 (9.3%) 5 (6.7%)
Direct invasion adjacent organs [0.99
No 70 (98.6%) 70 (98.6%)
Yes 1 (1.4%) 1 (1.4%)
Major vascular resection 0.31
No 69 (92.0%) 71 (95.9%)
Yes 6 (8.0%) 3 (4.1%)
Bile-duct resection 0.56
No 69 (97.2%) 70 (98.6%)
Yes 2 (2.8%) 1 (1.4%)
Grade 0.51
Well/moderate 67 (93.1%) 63 (90.0%)
Poorly/undifferentiated 5 (6.9%) 7 (10.0%)
Microvascular invasion 0.82
No 62 (83.8%) 63 (85.1%)
Yes 12 (16.2%) 11 (14.9%)
Perineural invasion 0.15
No 63 (87.5%) 68 (94.4%)
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the setting of cirrhosis and HCC has not been clinically
relevant. The topic of lymphadenectomy is much more
relevant among ICC patients as the 8th edition of the AJCC
staging system now recommends that surgeons perform a
lymphadenectomy [13]. The current study was important
because it specifically examined peri-operative outcomes
of that subset of ICC patients who had concomitant cir-
rhosis. While the incidence of any complication was not
higher among patients who had cirrhosis, this group of
patients was more likely to undergo a minor versus major
hepatectomy. Interestingly, while roughly half of patients
without cirrhosis underwent a lymphadenectomy, only
about 20% of patients with cirrhosis had any LNH at the
time of surgery. When lymph nodes were indeed evaluated,
however, the incidence of MLN was comparable among
patients who did and did not have cirrhosis. On propensity
score matching analysis, lymphadenectomy was associated
with an increased risk of morbidity among patients with
cirrhosis compared with patients who did not have cir-
rhosis. To our knowledge, these data are the first to
examine specifically the topic of lymphadenectomy for
ICC among patients with cirrhosis.
A recent population-based study using the National
Health and Nutrition Survey data estimated that the
prevalence of cirrhosis was approximately 0.27% in the
USA [20]. The authors also noted that male sex and older
age were independently associated with the risk of cirrhosis
[20]. In the current study, we noted that the incidence of
Table 4 continued
Variables Non-cirrhosis
N (%)
Cirrhosis
N (%)
p value
Yes 9 (12.5%) 4 (5.6%)
Multi-focal 0.56
No 67 (89.3%) 69 (92.0%)
Yes 8 (10.7%) 6 (8.0%)
Ca 19–9, median (IQR) 30 (12–77) 33 (17–66) 0.27
CEA, median (IQR) 2.4 (1.6–3.4) 2.3 (1.6–3.7) 0.40
Complication [0.99
No 51 (68.0%) 51 (68.0%)
Yes 24 (32.0%) 24 (32.0%)
Clavien–Dindo grade of complication* 0.08
1–2 23 (95.8%) 19 (79.2%)
C3 1 (4.2%) 5 (20.8%)
Length of stay, median (IQR) 14 (10–17) 14 (11–20) 0.034
Overall survival, 5 year (95% CI) 50.0% (35.0–63.3) 48.7% (35.8–60.5) 0.39
*N = 48 patients who had postoperative complications
NA not available, CI confidence interval
Fig. 1 Incidence of complications stratified by lymphadenectomy among a patients with no cirrhosis (n = 75), b patients with cirrhosis
(n = 75) in the propensity-matched cohort
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cirrhosis among ICC patients was higher among men, yet
the median age of patients with ICC and cirrhosis was
younger than non-cirrhotic patients. Cirrhosis is an
important risk factor for ICC, as several studies have
reported a strong association between cirrhosis and ICC
[21–23]. Several studies from Eastern countries have noted
an incidence of cirrhosis as high as 20–25% among patients
with ICC [24, 25]. Conversely, in most Western series, the
incidence of cirrhosis has been somewhat lower at about
10% [26–28]. In the current study, roughly 1 in 10 patients
who had ICC also had pathological evidence of underlying
cirrhosis. Differences in the reported incidences of cir-
rhosis are undoubtedly multi-factorial and may be related
to regional epidemiological differences in terms of inci-
dence of environmental risk factors (e.g., hepatitis, obesity,
and hepatolithiasis). The ‘‘intermediate’’ incidence of cir-
rhosis reported in the current study likely reflects the multi-
national character of our database. In fact, in our study
cohort, the incidence of cirrhotic patients was 2.9% among
centers in the USA versus 9.5% among European centers
and 19.2% among Eastern centers (p\ 0.001).
Perhaps not surprisingly, there were several differences
in the baseline clinicopathological and surgical character-
istics among cirrhotic versus non-cirrhotic patients. For
example, the size of ICC tumors was smaller among
patients with cirrhosis. Patients who had cirrhosis under-
went fewer major hepatectomies, as well as were less likely
to have a concomitant major vascular (D = -7%) or bile-
duct (D = -17%) resection. In addition, patients with
cirrhosis were also less likely to undergo lymphadenec-
tomy (D = -30%). Previous data from our own group had
noted that utilization of lymphadenectomy among patients
with ICC varied considerably [29–31]. In fact, the odds of
performing a lymphadenectomy has increase over time as
more and more surgeons have accepted the importance of
nodal staging for ICC [32]. Furthermore, surgeons are more
prone to perform a lymphadenectomy among patients with
more advanced T-stage disease [32]. The current study
expands on this previous work as it noted that the presence
of cirrhosis also significantly influenced the surgical deci-
sion to perform a lymphadenectomy. In fact, patients with
cirrhosis were about a third less likely to have a lymph
node evaluated. These data are important especially in light
of the finding that when lymphadenectomy was performed,
the chance of finding metastatic disease in the nodal basin
was comparable among cirrhotic and non-cirrhotic patients.
Given the varied baseline clinical and surgical details
among cirrhotic and non-cirrhotic patients, a propensity
score match analysis was performed to obtain a more
comparable cohort of patients. Among the 150 propensity-
matched patients, the overall incidence of morbidity was
comparable among cirrhotic and non-cirrhotic patients
(&30%). Of note, the incidence of severe complication
(Clavien–Dindo grade C 3) was, however, fivefold higher
among patients with cirrhosis compared with non-cirrhotic
patients (non-cirrhosis 4.2% vs. cirrhosis 20.8%). Inter-
estingly, among non-cirrhotic patients, there was no dif-
ference in the risk of morbidity among patients with or
without lymphadenectomy. In contrast, among patients
who had cirrhosis, the risk of a complication was roughly
threefold higher among patients who had a lymphadenec-
tomy (71%) compared with patients who did not have a
lymphadenectomy (23%) (p\ 0.001). These data are
consistent with findings from previous studies that have
evaluated lymphadenectomy and cirrhosis for other
malignancies [14–16]. In one study that examined patients
with gastric cancer, the authors reported that lym-
phadenectomy in the presence of cirrhosis was associated
Fig. 2 a Number of lymph node harvested among patients with no cirrhosis (n = 75) versus patients with cirrhosis (n = 75) in the propensity-
matched cohort. b Number of lymph node harvested among patients who had no complications (n = 102) versus patients who experience at
least one complication (n = 48)
2558 World J Surg (2018) 42:2551–2560
123
with a great risk of complications including infection and
ascites [15]. Interestingly, in the current study we similarly
noted that lymphadenectomy in the setting of cirrhosis was
associated with a higher risk of infection, yet not ascites.
As such, the data would collectively suggest that the ben-
efit of lymphadenectomy in cirrhotic patients should be
considered relative to the somewhat higher morbidity.
Several limitations should be considered when inter-
preting the results. Given the retrospective design and the
multicenter nature of the study, selection bias was possible.
Undoubtedly, there were some patients with cirrhosis who
were not offered surgery due to the poor underlying quality
of their non-tumorous hepatic parenchyma. In addition,
only Child–Pugh Class A patients were included in the
current study and therefore the results should not be
extrapolated to patients with more advanced cirrhosis. The
study cohort also included patients who underwent liver
surgery at one of fourteen hepatobiliary centers in the USA,
Europe, Australia, and Asia. The results from the current
study may therefore not be generalizable to non-academic,
community centers or lower volume hepatobiliary centers.
In conclusion, the incidence of cirrhosis among ICC
patients undergoing surgical management was 12%. The
incidence of cirrhosis varied somewhat by center and
geographic region. Patients who had cirrhosis were less
likely to undergo a major hepatectomy and were about one-
third less likely to undergo lymphadenectomy at the time of
surgery. The incidence of MLN was comparable among
cirrhotic and non-cirrhotic patients when lymph-node
evaluation was performed. On propensity matching, even
after controlling for competing risk factors, patients with
cirrhosis had a higher likelihood of complications when a
lymphadenectomy was performed. As such, the AJCC 8th
edition recommendation to perform an extended lymph-
node harvest should be considered in light of these data
when operating on patients with ICC and cirrhosis.
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